Reply

Resposta

We thank Dr. Josef Finsterer for his comments that completed our paper¹.

The scope of the paper was to present a review of pharmacological therapy of Duchenne muscular dystrophy (DMD). We agree that the points raised by Dr. Finsterer are very important, as we point out in the conclusion of the paper. Due to policies of the Arquivos de Neuropsiquiatria, the paper was in the limit of words and references for review articles. For this reason, it was not possible to extend the discussion about investigation and treatment of other aspects of DMD as he has pointed out and as it is performed in our center^2,3.

References

• ¹
  Werneck LC, Lorenzoni PJ, Ducci RD, Fustes OH, Kay CSK, Scola RH. Duchenne muscular dystrophy: an historical treatment review. Arq Neuropsiquiatr. 2019 Sep;77(8):579-89. https://doi.org/10.1590/0004-282X20190088
  » https://doi.org/https://doi.org/10.1590/0004-282X20190088
• ²
  Cirino RHD, Scola RH, Ducci RD, Wermelinger ACC, Kay CSK, Lorenzoni PJ, et al. Predictors of early left ventricular systolic dysfunction in Duchenne muscular dystrophy. Muscle Nerve. 2018 Jul;58(1):84-9. https://doi.org/10.1002/mus.26102
  » https://doi.org/https://doi.org/10.1002/mus.26102
• ³
  Cirino RHD, Scola RH, Ducci RD, Camarozano AC, Kay CSK, Lorenzoni PJ, et al. Evaluation of left-sided heart chambers with novel echochardiographic techniques in men with Duchenne and Becker muscular dystrophy. Am J Cardiol. 2019 Mar;123(6):972-8. https://doi.org/10.1016/j.amjcard.2018.12.011
  » https://doi.org/https://doi.org/10.1016/j.amjcard.2018.12.011

Publication Dates

• Publication in this collection
  29 May 2020
• Date of issue
  May 2020

History

• Received
  24 Mar 2020
• Accepted
  25 Mar 2020